1. Adams K.F., Ghali J.K., Patterson J.H., Stough W.J., Butler J., Bauman J.L., Ventura Y., Sabbah H., Mackowiak J.I., Veldhuisen D.J. A perspective on re-evaluating digoxin's role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profile. Eur J Heart Fail, 2014, vol. 16, no. 5, pp. 483-493. doi: 10.1002/ejhf.64.
2. Ambrosy A.P., Braunwald E., Morrow D.A., DeVore A.D. McCague K., Meng X., Duffy C.I., Rocha R., Velazquez E.J. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. J Am Coll Cardiol, 2020, vol. 76, no. 9, pp.1034-1048. doi: 10.1016/j.jacc.2020.06.073.
3. Ambrosy A.P., DeVore A.D., Velazquez E.J. In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time. Eur J Heart Fail, 2019, vol. 21, no. 8, pp.1008-1011. doi: 10.1002/ejhf.1540.
4. Bavishi C., KhanA.R., Ather S. Digoxin in patients with atrial fibrillation and heart failure: a meta-analysis. Int J Cardiol, 2015, vol. 188, pp. 99-101. doi: 10.1016/j.ijcard.2015.04.031.
5. Böhm M., Borer J., Ford I., Gonzalez-Juanatey J.R., Komajda M., Lopez-Sendon J, Reil J-C, Swedberg K, Tavazzi L. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol, 2013, vol. 102, no. 1, pp. 11-22. doi: 10.1007/s00392-012-0467-8.
6. Burnett H., Earley A., Voors A., Senni M., McMurray J.J.V., Deschaseaux C., Cope S. Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis. Circ Heart Fail, 2017, vol. 10, no. 1, pp. e003529. doi: 10.1161/CIRCHEARTFAILURE.116.003529.
7. Chatterjee S., Biondi-Zoccai G., Abbate A., D'Ascenzo F., Castagno D., Van Tassell B., Mukherjee D., Lichstein E. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ, 2013, vol. 16, no. 346, pp. f55. doi: 10.1136/bmj.f55.
8. Cunningham J.W., Claggett B.L., O'Meara E., Prescott M.F., Pfeffer M.A., Shah S.J., Redfield M.M., Zannad F., Chiang L.M., Rizkala A.R., Victor C Shi V.C., Lefkowitz M.P., Rouleau J., McMurray J., Solomon S.D., Zile M.R. Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. J Am Coll Cardiol, 2020, vol. 76, no. 5, pp.503-514. doi: 10.1016/j.jacc.2020.05.072.
9. Cunningham J.W., Vaduganathan M., Claggett B.L., Zile M.R., Anand I.S., Packer M., Zannad F., Lam C., Janssens S., Jhund P.S., Kober L., Rouleau J., Shah S.J., Chopra V.K., Shi V.C., Lefkowitz M.P., Prescott M.F., Pfeffer M.A., McMurray J., Solomon S.D. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail, 2020, vol. 8, no. 5, pp. 372-381. doi: 10.1016/j.jchf.2020.03.002.
10. Desai A.S., Solomon S.D., Shah A.M., Claggett B.L., Fang J.C., Izzo J., McCague K., Abbas C.A., Rocha R., Mitchell G.F. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA, 2019, vol. 322, no. 11, pp. 1-10. doi: 10.1001/jama.2019.12843.
11. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med, 1997, vol. 336, no. 8, pp. 525-533. doi: 10.1056/NEJM199702203360801.
12. Drazner M.H. Angiotensin Receptor-Neprilysin Inhibition (ARNI) Therapy and Reverse Remodeling in Heart Failure With Reduced Ejection Fraction. JAMA, 2019, vol. 322, no. 11, pp. 1051-1053. doi: 10.1001/jama.2019.12662.
13. Dunlay S.M., Roger V.L. Understanding the epidemic of heart failure: past, present, and future. Curr Heart Fail Rep, 2014, vol. 11, no. 4, pp. 404-415. doi: 10.1007/s11897-014-0220-x.
14. Faris R., Flather M., Purcell H., Henein M., Poole-Wilson P., Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol, 2002, vol. 82, no. 2, pp. 149-158. doi: 10.1016/s0167-5273(01)00600-3.
15. Faris R., Flather M., Purcell H., Poole-Wilson P., Coats A. Diuretics for heart failure. Cochrane Database Syst Rev, 2012, vol. 15, no. 2, pp. CD003838. doi: 10.1002/14651858.CD003838.pub3.
16. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA, 1995, vol. 273, pp. 1450-456.
17. Gaziano T.A., Fonarow G.C., Velazquez E.J., Morrow D.A., Braunwald E., Solomon S.D. Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. JAMA Cardiol, 2020. doi: 10.1001/jamacardio.2020.2822. Online ahead of print.
18. Gheorghiade M., Shah A.N., Vaduganathan M., Butler J., Bonow R.O., Rosano G.M.C., Taylor S., Kupfer S., Misselwitz F., Sharma A., Fonarow G.C. Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics’, clinicians’, industry’s, regulators’, and payers’ perspectives. Heart Fail Clin, 2013, vol. 9, no. 3, pp.285-290. doi: 10.1016/j.hfc.2013.05.002.
19. Gori M., Volterrani M., Piepoli M., Senni M. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs. Int J Cardiol, 2017, vol. 226, pp. 136-140. doi: 10.1016/j.ijcard.2016.06.083.
20. Januzzi Jr J.L., Prescott M.F., Butler J., Felker G.M., Maisel A.S., McCague K., Camacho A., Piña I.L., Rocha R.A., Shah A.M., Williamson K.M., Solomon S.D. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA, 2019, vol. 322, no. 11, pp. 1-11. doi: 10.1001/jama.2019.12821.
21. Kazuomi K. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond. Curr Cardiol Rep, 2018, vol. 20, no. 5. doi: 10.1007/s11886-018-0944-4.
22. Maggioni A.P., Anker S.D., Dahlstrom U., Filippatos G., Ponikowski P., Zannad F., Amir O., Chioncel O., Leiro M.C., Drozdz J., Erglis A., Fazlibegovic E., Fonseca C., Fruhwald F., Gatzov P., Goncalvesova E., Hassanein M., Hradec J., Kavoliuniene A., Lainscak M., Logeart D., Merkely B., Metra M., Persson H., Seferovic P., Temizhan A., Tousoulis D., Tavazzi L. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail, 2013, vol. 15, no. 10, pp. 1173-1184. doi: 10.1093/eurjhf/hft134.
23. Maisel A., Mueller C., Adams K., Anker S.D., Aspromonte N., Cleland J.G.F., Cohen-Solal A., Dahlstrom U., DeMaria A., DiSomma S., Filippatos G.S., Fonarow G.C., Jourdain P., Komajda M., Liu P.P., McDonagh T., McDonald K., Mebazaa A., Nieminen M.S., Peacock W.F., Tubaro M., Valle R., Vanderhyden M., Yancy C.W., Zannad F.,Braunwald E. State of the ar t: using natriuretic peptide levels in clinical prac tice. Eur J Heart Fail, 2008, vol. 10, no. 9, pp. 824-839. doi: 10.1016/j.ejheart.2008.07.014.
24. McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L., Shi V.C., Solomon S.D., Swedberg K., Zile M.R. Angiotensin-neprilysin inhibition versus enalapril in hear t failure. N Engl J Med, 2014, vol. 371, no. 11, pp. 993-1004.
25. Miles J.A., Hanumanthu B.K., Patel K., Chen M., Siegel R.M., Kokkinidis D.J. Torsemide versus furosemide and intermediate-term outcomes in patients with heart failure: an updated meta-analysis. J Cardiovasc Med, 2019, vol. 20, no. 6, pp. 379-388. doi: 10.2459/JCM.0000000000000794.
26. Miller L.V., Missov E.D. Epidemiology of heart failure. Cardiol Clin, 2001, vol. 19, no. 4, pp. 547-555. doi: 10.1016/s0733-8651(05)70242-3.
27. Morrow D.A., Velazquez E.J., DeVore A.D., Desai A.S., Duffy C.I., Ambrosy A.P., Gurmu Y., McCague K., Rocha R., Braunwald E. Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. Circulation, 2019, vol. 139, no. 19, pp. 2285-2288. doi: 10.1161/CIRCULATIONAHA.118.039331.
28. Nochioka K., Sakata Y., Shimokawa H. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure. Adv Exp Med Biol, 2018, vol. 1067, pp. 17-30. doi: 10.1007/5584_2018_179.
29. Orso F., Fabbri G., Maggioni A. Epidemiology of Heart Failure. Handb Exp Pharmacol, 2017, vol. 243, pp. 15-33. doi: 10.1007/164_2016_74.
30. Papademetriou V., Toumpourleka M., Imprialos K.P., Alataki S., Manafis A., Stavropoulos K. The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction. Curr Pharm Des, 2018, vol. 24, no. 46, pp. 5517-5524. doi: 10.2174/1381612825666190219141326.
31. Pascual-Figal D., Wachter R., Senni M., Bao W., Noè A., Schwende H., Butylin D., Prescott M.F. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study. JACC Heart Fail, 2020, vol. 8, no. 10, pp. 822-833. doi: 10.1016/j.jchf.2020.05.012.
32. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J., Coats A., Falk V., González-Juanatey J.R., Harjola V.P., Jankowska E.A., Jessup M., Linde C., Nihoyannopoulos P., Parissis J.T., Pieske B., Riley J.P., Rosano G., Ruilope L.M., Ruschitzka F., Rutten F.H., Van Der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur J Heart Fail, 2016, vol. 18, no. 8, pp. 891-975. doi: 10.1002/ejhf.592.